Navigation Links
Acorda's Ampyra Sustains High Levels of Interest Seven Months After Launch With Favorable Future Share Projections
Date:12/13/2010

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that on most metrics, perceptions of Acorda's Ampyra, the first FDA-approved product for the management of a multiple sclerosis (MS) symptom, have remained consistent or improved since earlier waves, including product awareness, interest, satisfaction, the managed care process and Acorda's patient support program. Compared to early in the launch, patient requests play a less impactful role in Ampyra uptake. With increased familiarity after seven months on the market, neurologists are gaining a clear picture of the discontinuation rates, responder rates and insurance dynamics associated with Ampyra.

The recently released third and final wave of the LaunchTrends®: Ampyra report series finds that about half of the surveyed neurologists had been detailed on Ampyra within the past month.  Those considered high prescribers of the brand recall dialogue related to reimbursement. While market share of Ampyra was not significantly different compared to the prior wave, the respondents report starting significantly more dalfampridine-naive patients on Ampyra compared to earlier waves. More than three-quarters of the surveyed neurologists currently prescribe Ampyra and projected market share increases for the brand are expected to come from both an expanded user base as well as increased use among current prescribers.

LaunchTrends®: Ampyra is a three wave syndicated report series designed to track the uptake of Acorda's Ampyra at one month, four months and seven months following its commercial availability. In the current wave of research, which measures Ampyra's market impact at seven month post-launch, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of 20 of the respondents in November 2010. BioTrends will continue to track the uptake of Ampyra in TreatmentTrends®: Multiple Sclerosis,
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
2. Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004
3. Tocotrienols Shown to be Effective in Lowering Fat Levels in Blood
4. U.S. FDA Approves New Oral Contraceptive That Also Raises Folate Levels
5. People at Intermediate Risk of Heart Disease With Elevated hsCRP Benefit From Statin Therapy Even if Cholesterol Levels are Normal
6. FDA Approves Drug to Treat Condition That Causes Elevated Ammonia Levels
7. Single Dose of Proprietary Adult Stem Cells Regenerates Damaged Pancreas and Reduces Blood Glucose Levels in Diabetes
8. New Published Study Shows Masimo Rainbow SET(R) Pulse CO-Oximetry(TM) Reliably Determines Carbon Monoxide Levels in the Blood
9. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
10. Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
11. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:7/21/2014)... 2014 iFitDress.com, a famous company of ... announced its exclusive collection of 2014 glitter evening ... for its brand new gowns. , iFitDress.com is one ... market. Its sales boomed in the recent years, not ... also because of the amicable services offered on its ...
(Date:7/21/2014)... MA (PRWEB) July 21, 2014 What ... extramarital affair have in common? You can find them ... Heart! The novel's main character, Miranda, lives on Martha’s ... meets Clay, a wealthy New Yorker, and becomes entangled ... of the Heart challenges readers to think about what ...
(Date:7/21/2014)... Executives from Advice Media, the ... healthcare practices, will participate in this week’s International ... showcasing their state-of-the-art capabilities and successes in implementing ... the United States as the importance for doctors ... Advice Media’s presence at IACA comes on the ...
(Date:7/21/2014)... Press-NORC Center for Public Affairs Research has released the ... about what it means to be a quality health ... by the Robert Wood Johnson Foundation, sheds new light ... health care and doctors, as well as the information ... The survey produces new and actionable data during a ...
(Date:7/21/2014)... 21, 2014 (HealthDay News) -- Good parenting and ... children from low-income families, a new study suggests. ... children, and can lead to a number of ... health problems in both childhood and adulthood involve ... diabetes, heart disease, allergies and some cancers," study ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2
... unclear why it’s so, scientists at Johns Hopkins have linked ... tough//, protective casing that houses insects and worms to the ... ,A team of Hopkins sinus experts has found that the ... to 250 times more active in people with severe sinus ...
... say that there is nothing that matches gambling. Not even ... addict//. ,There has been an upsurge of gambling ... with gambling problems. According to some experts, this has led ... ,"It's related to other addictions, like alcoholism and tobacco addiction. ...
... may no longer be included in the specialist category, if ... ,A few radiologists who have had the opportunity ... them as part of the team. But the rest are ... physicians are unable to seek employment in breast clinics. And ...
... common man has seen a rapid increase in healthcare charges ... been affected not only by the rising cost of living// ... money-spinning business. ,The government in 2003 revised the ... had the benefit of ‘free’ hospital visits. In fact, they ...
... 10, sent a warning against dengue fever in the midst ... capital//. ,From this year’s January 1 to ... been reported, said the department. ,In order ... collaboration with the local officials of the affected areas, according ...
... and Drug Administration has charged the American Red Cross yet ... to the stipulation of safe blood collection techniques.// The Red ... the nation's requirement of blood, has been under the vigilance ... make the blood safe by enhancing the quality control system., ...
Cached Medicine News:Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 2Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 3Health News:Immune Response Linked to “Ghost” Parasites and Severely Congested Sinus 4Health News:Compulsive Gambling – a psychiatric disorde 2Health News:Escalating Healthcare charges in UAE 2Health News:Escalating Healthcare charges in UAE 3Health News:‘Search and Destroy’ operation against dengue mosquitoes in Philippin 2
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: